With sales of its lone product in a precipitous decline in the United States, Amarin has turned to an experienced local ...

La., has come out critical of Robert F. | Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s ...

Publicis Health has snapped up another Omnicom Health Group executive. | Publicis Health has snapped up another Omnicom ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

The new U.K. office will join more than a dozen others across the pond, including in Paris, Milan, Amsterdam and more. Elsewhere, The Bloc holds several offices in the Asia-Pacific region and both ...

For the life sciences sector, the new initiatives are meant to work in concert with the upcoming 10-year plan for the ...

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

Ratio Therapeutics and Ionetix have inked separate deals to boost production of the much-needed radioisotope actinium-225, ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Life sciences commercial teams are drowning in data complexity. | ciATHENA eliminates the traditional barriers between ...

In CNS research, where qualitative endpoint variability can significantly affect a trial’s outcome, the role of eCOA is ...

In the wake of Marks' exit, FDA commissioner Marty Makary, M.D., named Vinay Prasad, M.D., to head up CBER. In addition to that title, Prasad recently added the title of "chief medical and science ...